Clinical Trials Browser

Phase 1 × prexasertib × Clear all

NCT04023669 2025-02-07

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Phase 1 Completed

Microphthalmia, Isolated, with Coloboma 5, Brain Neoplasms, Medulloblastoma, Central Nervous System Neoplasms

NCT02808650 2023-12-20

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

30 enrolled 16 charts

Central Nervous System Neoplasms

NCT02649764 2023-10-04

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT03495323 2021-04-15

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02124148 2020-04-01

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT02778126 2019-08-01

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

Phase 1 Completed

Advanced Cancer

NCT03735446 2019-06-12

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02555644 2019-02-15

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Phase 1 Completed

Head and Neck Neoplasms, Neoplasms

NCT02860780 2018-12-14

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT02514603 2017-05-22

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Phase 1 Completed

Neoplasm Metastasis, Neoplasms

NCT01115790 2016-05-10

A Phase 1 Study in Participants With Advanced Cancer

Phase 1 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell